Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + lenvatinib for high-risk locally advanced cervical cancer (EMBRACE high risk)
2023-506982-73-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in Cervical Cancer (CC), sponsored by Erasmus MC. Primary endpoint: Progression-free survival rate at 24 months. Planned start Nov 2025; status: authorised.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2023-506982-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506982-73-00.